Posts tagged MDS
Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.

Read More
Leerink resumes coverage of Kura at outperform

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday.

“We view Kura's lead pipeline program, tipifarnib (a farnesyltransferase inhibitor) as a safe and active drug,” writes analyst Jonathan Chang.

Read More